Condition: Extensive Stage Small Cell Lung Cancer · Sponsor: Amgen
The primary objective of this study is to evaluate the safety and tolerability of subcutaneous (SC) tarlatamab.
This description comes directly from the study's public registry record.
Amgen Call Center · 866-572-6436 · medinfo@amgen.com
Always discuss trial participation with your own doctor first.
| University of Southern California, Norris Comprehensive Cancer Center | Los Angeles, California, United States | Recruiting |
| University of Illinois Chicago | Chicago, Illinois, United States | Recruiting |
| Trinity Health Saint Joseph Mercy Ann Arbor | Ann Arbor, Michigan, United States | Recruiting |
| Avera Cancer Institute | Sioux Falls, South Dakota, United States | Recruiting |
| University of Texas MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| Swedish Cancer Institute | Seattle, Washington, United States | Recruiting |
| Chris OBrien Lifehouse | Camperdown, New South Wales, Australia | Recruiting |
| Calvary Mater Newcastle Hospital | Waratah, New South Wales, Australia | Recruiting |
| The Alfred Hospital | Melbourne, Victoria, Australia | Recruiting |
| Universitair Ziekenhuis Gent | Ghent, Belgium | Recruiting |
| Universitair Ziekenhuis Leuven - Campus Gasthuisberg | Leuven, Belgium | Recruiting |
| Centre Hospitalier Universitaire de Liege - Sart Tilman | Liège, Belgium | Recruiting |
+ 19 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06598306